Search Results - "Abalos, R.M."

Novel prophylactic and therapeutic vaccine against tuberculosis by Okada, Masaji, Kita, Yoko, Nakajima, Toshihiro, Kanamaru, Noriko, Hashimoto, Satomi, Nagasawa, Tetsuji, Kaneda, Yasufumi, Yoshida, Shigeto, Nishida, Yasuko, Nakatani, Hitoshi, Takao, Kyoko, Kishigami, Chie, Inoue, Yoshikazu, Matsumoto, Makoto, McMurray, David N, dela Cruz, E.C, Tan, E.V, Abalos, R.M, Burgos, J.A, Saunderson, Paul, Sakatani, Mitsunori

“…Abstract We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and…”
Get full text

Evaluation of a novel vaccine (HVJ–liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB by Okada, Masaji, Kita, Yoko, Nakajima, Toshihiro, Kanamaru, Noriko, Hashimoto, Satomi, Nagasawa, Tetsuji, Kaneda, Yasufumi, Yoshida, Shigeto, Nishida, Yasuko, Fukamizu, Reiko, Tsunai, Yoshie, Inoue, Ruriko, Nakatani, Hitoshi, Namie, Yumi, Yamada, Junko, Takao, Kyoko, Asai, Ritsuko, Asaki, Ryoko, Matsumoto, Makoto, McMurray, David N, Dela Cruz, E.C, Tan, E.V, Abalos, R.M, Burgos, J.A, Gelber, Robert, Sakatani, Mitsunori

“…Abstract We have developed a novel tuberculosis (TB) vaccine; a combination of the DNA vaccines expressing mycobacterial heat shock protein 65 (HSP65) and…”
Get full text

Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models by Kita, Yoko, Okada, Masaji, Nakajima, Toshihiro, Kanamaru, Noriko, Hashimoto, Satomi, Nagasawa, Tetsuji, Kaneda, Yasufumi, Yoshida, Shigeto, Nishida, Yasuko, Nakatani, Hitoshi, Takao, Kyoko, Kishigami, Chie, Nishimatsu, Shiho, Sekine, Yuki, Takamori, Yasushi, McMurray, David N., De la Cruz, E.C., Tan, E.V., Abalos, R.M., Burgos, J.A., Saunderson, Paul, Sakatani, Mitsunori

“…[Purpose] BCG is not efficacious against M. tuberculosis (TB) in adult. Therefore, novel TB vaccines were established by using three kinds of animal models…”
Get full text

Novel therapeutic vaccine: Granulysin and new DNA vaccine against Tuberculosis by Okada, Masaji, Kita, Yoko, Nakajima, Toshihiro, Kanamaru, Noriko, Hashimoto, Satomi, Nagasawa, Tetsuji, Kaneda, Yasufumi, Yoshida, Shigeto, Nishida, Yasuko, Nakatani, Hitoshi, Takao, Kyoko, Kishigami, Chie, Nishimatsu, Shiho, Sekine, Yuki, Inoue, Yoshikazu, Matsumoto, Makoto, McMurray, David N., De la Cruz, E.C., Tan, E.V., Abalos, R.M., Burgos, J.A., Saunderson, Paul, Sakatani, Mitsunori

“…[Purpose] Multi-drug resistant (MDR) Mycobacterium Tuberculosis (M.TB) is a big problem in the world. We have developed novel TB therapeutic vaccines. [Methods…”
Get full text

Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model by Kita, Yoko, Tanaka, Takao, Yoshida, Shigeto, Ohara, Naoya, Kaneda, Yasufumi, Kuwayama, Sachiko, Muraki, Yumiko, Kanamaru, Noriko, Hashimoto, Satomi, Takai, Hiroko, Okada, Chika, Fukunaga, Yukari, Sakaguchi, Yayoi, Furukawa, Izumi, Yamada, Kyoko, Inoue, Yoshikazu, Takemoto, Yuji, Naito, Mariko, Yamada, Takeshi, Matsumoto, Makoto, McMurray, David N., Cruz, E.C. Dela, Tan, E.V., Abalos, R.M., Burgos, J.A., Gelber, Robert, Skeiky, Yasir, Reed, Steven, Sakatani, Mitsunori, Okada, Masaji

“…We have developed two novel tuberculosis (TB) vaccines: a DNA vaccine combination expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12…”
Get full text

Recombinant interleukin-2 in lepromatous leprosy lesions: immunological and microbiological consequences by VILLAHERMOSA, L.G., ABALOS, R.M., WALSH, D.S., FAJARDO, T.T., WALSH, G.P.

“…Summary Seven patients with lepromatous leprosy (LL) were inoculated with recombinant interleukin‐2 (rIL‐2) at 5 lesional sites on the back, four sites…”
Get full text

Recombinant interleukin-2 in lepromatous leprosy lesions : immunological and microbiological consequences by VILLAHERMOSA, I. G, ABALOS, R. M, WALSH, D. S, FAJARDO, T. T, WALSH, G. P

“…Seven patients with lepromatous leprosy (LL) were inoculated with recombinant interleukin-2 (rIL-2) at 5 lesional sites on the back, four sites receiving one…”
Get full text